Title page

Baseline Characteristics and Outcomes of 180 Egyptian COVID-19 Patients Admitted to Quarantine Hospitals of Ain Shams University: A Retrospective Comparative Study

Running title: COVID-19 in Egypt

Sara I. Taha [a], Sara F. Samaan[b], Aalaa K. Shata [c], Shereen A. Baioumy [d], Shaimaa A. Abdalgeleel [e], Mariam K. Youssef [a]*

[a] Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
[b] Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
[c] Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
[d] Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Egypt.
[e] Department of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt.

Authors:

Sara Ibrahim Taha, M.D., Ph.D.
Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
E-mail: dr_sara_ib@med.asu.edu.eg   ORCID: https://orcid.org/0000-0001-8224-8701

Sara Farid Samaan, M.D., Ph.D.
Lecturer of Internal Medicine/ Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
E-mail: Dr.sara_farid@yahoo.com

Aalaa Kamal Shata, M.D., Ph.D.
Lecturer of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.
E-mail: aalaashata@yahoo.com

Shereen Atef Baioumy, M.D., Ph.D.
Lecturer of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Email: drshereenatef@yahoo.com   ORCID: https://orcid.org/0000-0002-2188-6790

Shaimaa Abdalaleem Abdalgeleel, M.D., Ph.D.
Lecturer of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt.
E-mail: shaimaa.abdalgeleel@nci.cu.edu.eg ORCID: https://orcid.org/0000-0003-0994-7703

Mariam Karam Youssef, M.D., Ph.D.
Lecturer of Clinical Pathology/Hematology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
E-mail: Dr.mariam_karam@hotmail.com   ORCID: https://orcid.org/0000-0003-2075-3889

[*] **Corresponding Author:**
Sara Ibrahim Taha, MD, PhD
Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University.
Address: Ain Shams University, Abassia, Cairo, Egypt
Office tel., fax: + (202) 24346308   Mobile: + (20) 1125360009
E-mail: dr_sara_ib@med.asu.edu.eg

https://orcid.org/0000-0001-8224-8701

Abstract:

Background: COVID-19 mortality, severity, and recovery are major global concerns, but they

are still insufficiently understood, particularly in the Middle East. **Methods:** This retrospective

study comprised 180 adult Egyptian COVID-19 patients who were categorized and compared to

evaluate if there was a link between their clinical and laboratory findings at hospital admission

and disease severity and mortality risk. **Results**: Of all patients enrolled, 27.8% had severe

disease and 13.9% died during their hospital stay. Diabetes mellitus (46.7%), hypertension

(36.1%) and chronic obstructive pulmonary disease (COPD) (33.3%) were the most frequent

associated co-morbidities. Severe patients and non-survivors were significantly older compared

to their corresponding groups. Their absolute neutrophil count, procalcitonin (PCT), ESR, C-

reactive protein (CRP), AST, ALT, LDH, D-dimer, and ferritin levels were all significantly

higher (P ≤ 0.05), whereas their absolute lymphocyte count was significantly lower (P ≤ 0.05).

COPD (OR: 3.294; 95% CI: 1.199-9.053; P= 0.021), diabetes mellitus (OR: 2.951; 95%

CI:1.070-8.137; P= 0.037), ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551; P= 0.001),

AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991; P= 0.021), CT-SS ≥ 17 (OR: 1.205; 95% CI:

1.089-1.334; P ≤ 0.001) and absolute lymphocyte count $< 1 \times 10^{3}/\mu L$ (OR: 4.002; 95% CI: 1.537-

10.421; P= 0.005), were all linked to a higher risk of COVID-19 severity. Furthermore, COVID-

19 in-hospital mortality was predicted by dyspnea (OR: 4.006; 95% CI: 1.045-15.359; P= 0.043),

CT-SS ≥ 17 (OR: 1.271; 95% CI: 1.091-1.482; P= 0.002) and AST ≥ 40 IU/L (OR: 2.89; 95%

CI: 1.091-7.661; P= 0.033). **Conclusions:** Clinical and laboratory data of COVID-19 patients at

their hospital admission may aid in identifying early risk factors for severe illness and a high

mortality rate, as well as determining the most effective management for them.

Keywords: Coronavirus; COVID-19; Egypt; Indicators; Mortality; Severity.

INTRODUCTION:

Coronavirus disease 2019 (COVID-19) is a highly contagious infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that was first discovered in Wuhan, China, in early December 2019. Since then, the disease has rapidly spread to become a global epidemic [1]. The first COVID-19 case in Egypt was reported in February 2020, and since then, the number of cases has been dramatically rising. According to the Egyptian Ministry of Health and Population, there were more than 266,000 confirmed COVID-19 cases and almost 15,200 COVID-19 deaths throughout Egypt and its governorates as of June 5, 2021 [2].

COVID-19 infection is most commonly transmitted through respiratory droplets, as well as human-to-human contact [3]. It causes a wide range of symptoms that can lead to patient mortality, making it difficult to treat and control [4]. It also depletes hospital resources, such as ICU beds and mechanical ventilators, especially in low-resource countries [5]. So far, no specific antiviral therapy for COVID-19 has been found to be effective, and clinical management is based primarily on symptom control [6]. Several vaccinations began to emerge toward the end of 2020. According to the World Health Organization (WHO), there were 102 vaccines in clinical trials and 184 vaccines in preclinical trials as of May 28, 2021 [7].

The goal of this study was to understand more about COVID-19 baseline features and outcomes in Egyptian patients, which could aid in detecting early risk factors for poor prognosis and guiding proper patient management.

METHODOLOGY:

Study subjects and settings

This retrospective study included 180 COVID-19 adult patients (age ≥ 18 years old) admitted

from March 1 to April 30, 2021 to the Quarantine Hospitals of Ain-Shams University (El-

demerdash hospital and Field hospital), Cairo, Egypt. Only confirmed SARS-CoV-2 cases

through nasopharyngeal swabs real-time reverse-transcriptase–polymerase-chain-reaction (RT–

PCR) assays, in accordance with WHO guidance [8], were enrolled in the study. Pregnant

women, patients with missing data and those who had hematological diseases or immunological

disorders were excluded from the study.

Data collection:

Baseline data including: age, gender, presenting symptoms, comorbidities and chronic diseases,

chest computed tomography (CT), ICU admission necessity, length of hospital stay and outcome

(survival or non-survival), as well as baseline routine laboratory test results (CBC with

differential counts, CRP, ESR, ferritin, D-dimer, PCT, LDH, AST and ALT) were acquired from

medical records of all included patients.

Before the start, The Ain Shams University Faculty of Medicine Research Ethics Committee

(REC) gave its permission for the study to be carried out. Informed consent was waived due to

the retrospective nature of this study. Data were collected from hospital records in an anonymous

pattern, kept private and confidential. They were solely utilized for the purpose of research.

Patient categorization:

All included patients were categorized according to guidelines of the management protocol of

COVID-19 patients released by Ain Shams University Hospitals [9]. Patients were considered to

have severe/critical disease if one or more of the following were present: oxygen saturation ≤

93% at rest; dyspnea with a respiratory rate ≥ 30 breath/min; arterial partial oxygen pressure

(PaO2)/fraction of inspired oxygen (FiO2) ≤ 300 mmHg; respiratory failure with a need for

mechanical ventilation; ICU admission need with shock, or organ failure syndrome. COVID-19

patients who did not meet these criteria but had a positive COVID-19 nucleic acid test were

classified as having mild to moderate disease severity (non-severe).

Calculation of CT scoring system:

Each of the five lung lobes was visually assessed for the extent of involvement, whether

unilateral or bilateral; peripheral, central, or both; upper lobe predominance, lower lobe

predominance, or both; and then graded on a scale of 0 to 5 (degree of involvement: 0%, less

than 5%, 5–25%, 26–49%, 50–75%, and > 75%, respectively). The sum of the individual lobar

grades was then used to create a score that ranged from 0 to 25 [10,11].

Statistical methods:

The results were generated using the Statistical Package of Social Science (SPSS) (version 26).

Quantitative numerical data were described as means and standard deviations (SD) or medians

and ranges. While qualitative data were described as frequencies and percentages. Comparisons

were done using the Mann-Whitney –U test or the Chi-square test or Fisher's exact test as

appropriate. The significant variables in the univariate analysis were subjected to stepwise

logistic regression, and the odds ratio (OR) and its 95% confidence intervals (CI) were calculated

to estimate the risk. Probability (p-value) ≤ 0.05 was considered significant.

RESULTS:

Demographics and associated co-morbidities:

A total of 180 COVID-19 patients were enrolled in this study. Their median (IQR) age was 48

years (15-94). Thirty five percent of the patients were males and 65% were females. The most

common associated co-morbidities were diabetes mellitus (46.7%), hypertension (36.1%) and

chronic obstructive pulmonary disease (COPD) (33.3%). Of all the studied population, 27.8%

(n=50) had severe disease and 13.9% (n=25) died during their hospital stay. Patients of these 2

subgroups were significantly older compared to non-severe patients (median: 60 years (IQR:22-

91) vs. 43 years (15-94); P=0.004) and survivors (57.0 years (27-80) vs 45.0 years (15-94);

P=0.005), respectively. In terms of sex, differences between the studied subgroups were not

significant. Demographics and associated co-morbidities are shown in **Table 1.**

Baseline clinical characteristics and patients' outcomes:

Table 2 shows baseline clinical characteristics and outcomes of all studied patients and

according to COVID-19 severity and mortality. The most frequent symptoms at admission were

fatigue (90.6%), myalgia (75.0%), arthralgia (73.9%), fever (69.4%), dyspnea (69.4%) and

cough (68.9%). Only dyspnea was significantly associated with COVID-19 in-hospital mortality

(88.0% vs. 66.5%; P= 0.030). Patients with severe COVID-19 had significantly higher rates of

thrombotic manifestations (38.0% vs. 22.3%; P=0.030), but no significant difference between

non-survivors and survivors was found (36.0% vs. 25.2%; P=0.255). Regarding CT-SS,

significantly higher scores were observed in severe patients (median: 21 (IQR: 5-23) vs. 15 (0-

24); P ≤ 0.001) and non-survivors (20 (0-24) vs. 7 (0-23); P ≤ 0.001) compared to their

corresponding groups.

In the 180 patients, the ICU admission rate was 30.6% with significant higher rates in severe

patients and non-survivors compared to non-severe patients (96.0% vs. 5.4%; P ≤ 0.001) and

survivors (80.0% vs. 22.6%; P ≤ 0.001). In hospital mortality rates were significantly higher with

severe compared to non-severe disease (32.0% vs. 6.9%; P ≤ 0.001). The median (IQR) duration

of hospital stay of all studied patients was 14 days (3-29), with significant longer durations in

severe patients (22 days (10-29) vs. 10 days (3-22); P ≤ 0.001) and non-survivors (22 days (3-29)

vs. 12 days (3-29); P=0.001) compared to their corresponding groups.

Laboratory findings:

Those with severe disease and non-survivors exhibited significantly higher (P ≤ 0.05)

coagulation function (D-dimer), inflammation (PCT, ESR, CRP, and ferritin), liver dysfunction

(AST and ALT), and tissue damage (LDH) compared to their corresponding groups. On the other

hand, their CBCs showed significantly lower absolute lymphocyte counts (P ≤ 0.05) with

significantly higher absolute neutrophil counts (P ≤ 0.05). There were no significant differences

(P > 0.05) in hemoglobin level, total leukocyte and platelet counts between the studied

categories. **Table 3** shows the biochemical and hematological characteristics of the included

patients.

Indicators of COVID-19 severity and in-hospital mortality:

In **table 4**, multivariate logistic regression analysis was used to identify independent prognosis

indicators associated with COVID-19 severity and in-hospital mortality. Predictors of COVID-

19 severity in the studied patients were presence of COPD (OR: 3.294; 95% CI: 1.199-9.053; P=

0.021) and diabetes mellitus (OR: 2.951; 95% CI:1.070-8.137; P= 0.037) as co-morbidities,

abnormal high values of ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551; P= 0.001),

AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991; P= 0.021) and CT-SS ≥ 17 (OR: 1.205; 95%

CI: 1.089-1.334; P ≤ 0.001), as well as low absolute lymphocyte count < $1 \times 10^3/\mu L$ (OR: 4.002;

95% CI: 1.537-10.421; P= 0.005). The presence of dyspnea as a presenting symptom (OR:

4.006; 95% CI: 1.045-15.359; P= 0.043), CT-SS ≥ 17 (OR: 1.271; 95% CI: 1.091-1.482; P=

0.002) and AST ≥ 40 IU/L (OR: 2.89; 95% CI: 1.091-7.661; P= 0.033) were also found to be

independent predictors of COVID-19 in-hospital mortality.

DISCUSSION:

In the current study, comprehensive data analysis on the demographic, clinical, laboratory and

radiological characteristics and outcomes of 180 hospitalized adult Egyptian COVID-19 patients

were presented. The non-severe cases of COVID-19 (72.2%), as well as the survivors (86.1%),

were by far the most prevalent in this study.

This study revealed that the severity and mortality of COVID-19 were significantly predominant

in the older age groups. This could be explained by the age-dependent decline in cell-mediated

and humoral immune functions, resulting from low-grade chronic inflammation [12], as well as

the increased risk of multi-organ failure in elderly individuals due to their lower ability to correct

for hypoxia [13]. In agreement with our findings, several studies reported that elderly patients

with COVID-19 are more likely to progress to severe disease with worse outcomes, compared to

young and middle-aged patients [14-16]. In contrast, Wang and colleagues couldn't link COVID-

19 severity or mortality to a certain age group [17].

According to several studies, COVID-19 has infected more males than females, [18,19]. Female

gender may be a protective factor, as evidenced by the fact that women have fewer harmful

habits than men, particularly smoking [20]. Females may also have stronger innate and adaptive

immune responses than males, making them more resistant to infections [21]. In terms of

COVID-19 severity and morality, our research found no significant differences between male

and female patients. Wang et al. and Fois et al., like us, discovered no gender differences in

disease severity or mortality [12,22].

Diabetes mellitus, hypertension, and COPD were the most common chronic disorders among

COVID-19 participants in our study. These co-morbidities were found to be strongly linked to

disease progression. In addition, the odds of COVID-19 severity were 3.294 and 2.951 folds

greater in COPD and diabetic patients, respectively. These findings were in line with a meta-

analysis research that found diabetes mellitus and hypertension to be of the most common

underlying disorders among COVID-19 patients who were hospitalized [23]. Consistent with our

findings, Marhl et al. found a greater risk of COVID-19 in diabetic individuals due to the related

dysregulation of angiotensin-converting enzyme-2 (ACE-2), liver dysfunction, and chronic

inflammation [24]. In addition, the elevated risk of COVID-19 infection in patients with pre-

existing cardiovascular illness may be due to a decrease in pro-inflammatory cytokines, which

leads to weakened immune function [25]. In previous studies on MERS-CoV-2, it was

discovered that the virus's particular receptor, dipeptidyl peptidase-4, was expressed at a higher

level in smokers and COPD patients [26]. Emami et al. suggested that COPD could be an

underlying factor that makes patients more prone to COVID-19 development [23], which is

similar to our findings. Zhang et al., on the other hand, were unable to relate COVID-19 to

COPD [27].

The most common symptoms found at admission of our COVID-19 patients were; fatigue

(90.6%), myalgia (75%), arthralgia (74%), fever (69.4%), dyspnea (69.4%), and cough (68.9%).

In accordance to our results, Ghweli and co-workers found that malaise, fever, dry cough, and

dyspnea, were the most common manifestations of COVID-19 [14]. Dyspnea was found to be a

significant prominent feature among the non-survivors in this study. Furthermore, the risk of

disease mortality was 4.006 times higher in patients who presented with dyspnea than in those

who did not. Similarly, Zheng et al. reported a significant positive association of dyspnea with

COVID-19 progression to death [28]. Also, a meta-analysis study reported similar findings and

recommended dyspnea rather than fever as an indicator of poor outcome in COVID-19 patients

[29].

Individuals with COVID-19 may have coagulation abnormalities, promoting a hypercoagulable

state and resulting in an increased rate of thrombotic and thromboembolic events [30]. Using

whole blood thromboelastography, Panigada et al. identified hypercoagulability features in

COVID-19 patients, such as a decrease in time to fibrin formation, a decrease in time to clot

formation, and an increase in clot strength [31]. In the context of these findings, a significant

proportion of severe patients in our study were presented with thrombotic manifestations at

admission to the hospital.

Severe patients tend to get priority hospitalization, with an increased need for oxygen

supplementation, intensive care, and even mechanical ventilation [18]. Similarly, in our study,

the length of hospital stay and the necessity for ICU admission were both considerably higher in

severe patients and non-survivors.

Regarding complete blood count in COVID-19, peripheral blood leukocyte and lymphocyte

counts are found to be normal or slightly reduced during the early phase of the disease, when

non-specific symptoms are present. Approximately 1 to 2 weeks from the onset of the initial

symptoms, when there is a surge in the clinical manifestations of the disease coinciding with a

pronounced systemic increase of inflammatory mediators and cytokines, significant lymphopenia

becomes evident [32]. Several factors may contribute to COVID-19-associated lymphopenia: the

virus may directly infect lymphocytes, resulting in their lysis; the markedly increased levels of

interleukins may promote lymphocyte apoptosis; the cytokine storm may be associated with

lymphoid organ atrophy; and the metabolic acidosis present in severe COVID-19 patients may

suppress the proliferation of lymphocytes [32].On the other hand, neutrophils are triggered by

virus-related inflammatory factors produced by lymphocytes and endothelial cells, releasing

large amounts of reactive oxygen species, neutrophil extracellular traps, and other cytotoxic

mediators, which may dampen the virus [33]. Also, platelets may have an important role in the

regulation of virus-mediated inflammatory process [34]. The platelet count of most mild to

moderate COVID19 patients may be normal or elevated but it may be reduced in critically ill

patients. In individuals with severe COVID19, thrombocytopenia may be caused by a decrease in

platelet production, an increase in platelet breakdown, or a decrease in circulating platelets [35].

In the current study, the hematological indices of the included COVID-19 patients revealed

significantly lower median absolute lymphocyte counts and higher median absolute neutrophil

counts; yet without neutrophilia, among severe patients and non-survivors. Also, lymphopenia <

$1 \times 10^3/\mu L$ was an independent predictor of disease severity (OR: 4.002). However, total

leukocytic count, hemoglobin level, and platelet counts showed no significant differences as the

disease progressed. In accordance to our results, lymphopenia has been recognized in many

studies as an effective and reliable indicator of severity and mortality in COVID-19 patients

[14,18,36]. Also, many studies reported that non-survivors presented with significantly higher

neutrophil counts [4,36,37]. Moreover, Shang et al. found that hemoglobin levels were not

influenced by the severity of the disease [38]. As opposed to our findings, Li et al. have found

significant leucopenia and thrombocytopenia in the severe patients [18]. In addition, Sulejmani et

al. reported significant leukocytosis in severe COVID-19 patients, which could be related to the

hyper-inflammatory state [39].

It has been reported that viral infection could induce an acute systemic inflammatory syndrome

characterized by fever and multiple organ dysfunction. Additionally, viral infection induces

acute phase reactant production [40]. CRP is an inflammatory marker that plays an important

role in host resistance to invading pathogens. Higher CRP values have been linked to several

unfavorable aspects of COVID-19 including, cardiac injury, respiratory distress, and death. The

detection of CRP levels was reported to be of great value in assessing the severity of COVID-19

patients [4]. Binding and storage of iron, which are functions of ferritin, are also associated with

immune and inflammatory response to viral infection [41]. Procalcitonin (PCT) has been

recently suggested as a valuable inflammatory prognostic biomarker in identifying COVID-19

patients at high risk for clinical deterioration [42]. Our findings revealed significantly higher

inflammatory and tissue damage markers (CRP, ESR, ferritin, PCT, and LDH) among severe

COVID-19 patients and those who died from the disease. Also, ferritin $\geq$ 350 ng/mL was an

independent predictor of COVID-19 severity with an odds ratio of 11.08. These findings were in

agreement with several other studies [4,18,41,42].

Coagulation disorders are relatively frequently encountered among severe COVID-19 patients.

The D-dimer dynamics can reflect disease severity and elevated D-dimer level is associated with

adverse patients' outcomes [14,30]. In accordance, D-dimer levels in our studied patients

increased significantly as the disease worsened.

One of the mechanisms by which COVID-19 can invade the human body is by binding to human

ACE-2 receptor with subsequent enhancement of ACE-2 expression in hepatocytes [43]. Chen et

al. discovered a slight increase in ALT and AST serum values in 43.4% of COVID-19 cases

from Wuhan, which was the first report of hepatic dysfunction in SARS-CoV-2 infection [36]. A

link between aberrant liver biochemistry and COVID-19 severity has recently been discovered

[18]. In a study in Shanghai, severe to critical cases exhibited significantly higher serum ALT

and AST levels than those who had mild to moderate COVID-19 [44]. In line with these

findings, the present study revealed significantly higher serum values of both ALT and AST

among severely infected COVID-19 patients and those who died from the disease. In addition,

AST $\geq$ 40 IU/L was an independent predictor of COVID-19 severity and mortality with an odds

ratio of 3.076 and 2.890, respectively.

The use of CT imaging for the diagnosis and grading of viral pneumonia, allows patients with

suspected SARS-CoV-2 infection to be isolated and treated in time for recovery, thus optimizing

patient management [45]. Ground-glass opacities, consolidations and Broncho vascular

thickening are characteristic chest CT findings in COVID-19 pneumonia. Atypical chest CT

features also include masses, nodules, cavitation, lymphadenopathy, and pleural effusion [46].

The CT-scoring system (CT-SS), which has a high predictive value for the dynamic changes in

chest CT exams in different severities of COVID-19 pneumonia [46], can be used to assess the

extent of lung involvement. Both lungs were divided into 12 zones in total in the scoring

methodology of Zhou et al; the degree of involvement in each lung zone was scored from 0 to 4,

with a maximum achievable score of 48 [47]. Yang and coworkers developed another scoring

system in which both lungs were divided into 20 zones and examined on chest CT using a

methodology that assigned scores of 0, 1, and 2; hence, the individual's total score may vary

from 0 to 40 points [48]. In this current study, the lung lobar involvement scoring system (0–25)

was used as it was practical and time-effective [10,11,46], and showed significantly higher

scores in the severe and non-survivor patients. Moreover, the odds of disease severity and

mortality were 1.205 and 1.271 folds higher with CT-SS of $\geq$ 17, respectively. In accordance to

our findings, in a study by Hafez et al., CT-SS 18/24 was considered the cutoff value among the

mild and severe cases [46]. Also, Francone et al. have stated that CT-SS of $\geq$ 18 is highly

predictive of COVID-19 mortality [10].

This study has some limitations that should be considered. First, it is a retrospective study that

was performed in a limited hospital setting and included a relatively small sample size with

disproportion in the different study groups. A large multi-center prospective observational study

would be better to authenticate our findings. Another limitation is that all data included in this

study were from the official records of the hospital; meanwhile, some patients have not been

hospitalized for treatment because of the lack of awareness of disease severity, as well as the

shortage of heath care facilities. A larger study that includes out-patients isolated at home in

addition to hospitalized in-patients, would offer a more representative study population.

CONCLUSIONS:

According to this study, COVID-19 infection was more aggressive in the elderly, diabetic,

hypertensive, and COPD patients, as well as in those with low lymphocyte counts, high

neutrophil counts, and high CRP, ESR, PCT, LDH, D-dimer, ferritin, AST, and ALT levels at

the time of their admission to hospital. Hence, pretreatment clinical and laboratory data from

COVID-19 patients at hospital admission may aid in identifying early risk factors for disease

progression, as well as determining the most effective management plan.

Abbreviations:

ACE-2: Angiotensin-converting enzyme-2; COPD: Chronic obstructive pulmonary disease;

COVID-19: Coronavirus disease 2019; CT-SS: CT-scoring system; RT- PCR: Reverse

transcription-polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome

corona virus 2; WHO: World Health Organization.

Manuscript word count: 3290 words

Abstract word count: 285 words

Tables: 4

Figures: 0

Data availability statement: Data will be available upon request.

Acknowledgement: None.

Conflicts of interest disclosure: None.

Funding sources: None

Consent for publication: Not applicable**.**

Authors contribution:

Sara I. Taha: conceptualization, methodology, writing- reviewing and editing; *Sara F. Samaan*

and Aalaa K. Shata: data curation, investigation; *Shereen A. Baioumy;* project visualization,

resources, software, validation; *Shaimaa A. Abdalgeleel:* formal analysis, supervision; *Mariam*

K. Youssef: writing-original draft preparation, project administration.

REFERENCES:

[1] Balkhair AA. COVID-19 pandemic: a new chapter in the history of infectious diseases.

Oman Med J; 202035(2): e123. DOI: 10.5001/omj.2020.41. PMID: 32328297; PMCID:

PMC7171815.

[2] Egyptian Ministry of Health. https://www.care.gov.eg/EgyptCare/Index.aspx. Accessed

5 June, 2021.

[3] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in

Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Mar

26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. PMID:31995857; PMCID:

PMC7121484.

[4] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected

with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395(10223):497-506.

doi: 10.1016/S0140-6736(20)30183-5. PMID: 31986264; PMCID: PMC7159299

[5] Heo, J., Han, D., Kim, HJ, Kim D, Lee YK, Lim D, et al. Prediction of patients requiring

intensive care for COVID-19: development and validation of an integer-based score

using data from Centers for Disease Control and Prevention of South Korea. J Intensive

Care. 2021 Jan 29;9(1):16. doi: 10.1186/s40560-021-00527-x. PMID: 33514443 PMCID:

PMC7844778.

[6] Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an

indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J

Transl Med. 2020 Oct 29;18(1):406. doi: 10.1186/s12967-020-02571-x. PMID:

33121497; PMCID: PMC7594951.

[7] World Health Organization. DRAFT landscape and tracker of COVID-19 candidate

vaccines. who.int. Update May 28, 2021. Accessed May 30,

2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-

vaccines.

[8] WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human

cases, interim guidance. 2020. p. 1–7. Available from: https://www.who.int/publications-

detail/laboratory-testing-for-2019-novel-coronavirus-in-sus-pected-human-cases-

20200117.

[9] Abdelfattah E, Ahmed S, El-Zahapy H, EL Said A, Salem S, Tharwat A, et al., Hospital

response to COVID-19 a consensus: Report on Ain Shams University Hospital Strategy.

[published online ahead of print, June 12, 2020]. ScienceOpen. doi:

https://doi.org/10.14293/S2199-1006.1.SOR-.PPD4QZX.v1

[10] Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L et al. Chest CT score in

COVID-19 patients: correlation with disease severity and short-term prognosis. Eur

Radiol. 2020; 4:1 – 10

[11] Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes at Chest

CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020;

295:715 –721.

[12] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,

China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum

in: JAMA. 2021 Mar 16;325(11):1113. PMID: 32031570; PMCID: PMC7042881.

[13] Zou Z, Yang Y, Chen J, Xin S, Zhang W, Zhou X, et al. Prognostic factors for severe

acute respiratory syndrome: a clinical analysis of 165 cases. Clin Infect Dis. 2004 Feb

15;38(4):483-9. doi: 10.1086/380973. Epub 2004 Jan 28. PMID: 14765339; PMCID:

PMC7107942.

[14] Ghweil AA, Hassan MH, Khodeary A, Mohamed AO, Mohammed HM, Abdelazez AA,

et al. Characteristics, Outcomes and Indicators of Severity for COVID-19 Among Sample

of ESNA Quarantine Hospital's Patients, Egypt: A Retrospective Study. Infect Drug

Resist. 2020 Jul 17; 13:2375-2383. doi: 10.2147/IDR.S263489. PMID: 32765012;

PMCID: PMC7381791.

[15] Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020 Jun;80(6):e14-e18. doi: 10.1016/j.jinf.2020.03.005. Epub 2020 Mar 27. PMID: 32171866; PMCID: PMC7102640.

[16] Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates. BMJ. 2020 Apr 1;369:m1327. doi: 10.1136/bmj.m1327. PMID: 32238354.

[17] Wang C, Deng R, Gou L, Fu Z, Zhang X, Shao F, et al. Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters. Ann Transl Med. 2020 May;8(9):593. doi: 10.21037/atm-20-3391. PMID: 32566620; PMCID: PMC7290538.

[18] Li X, Xu Z, Wang T, Xu X, Li H, Sun Q, et al. Clinical laboratory characteristics of severe patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021 Jan-Mar;9:184-190. doi: 10.1016/j.cegh.2020.08.012. Epub 2020 Sep 15. PMID: 32954048; PMCID: PMC7491425.

[19] Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. Chinese. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. PMID: 32064853.

[20] Manavi KR, Alston-Mills BP, Thompson MP. History of tobacco, vitamin D and women. Int J Vitam Nutr Res. 2020 Oct;90(5-6):389-394. doi: 10.1024/0300-9831/a000640. Epub 2020 Feb 24. PMID: 32091316.

[21] Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. Clin Rev Allergy Immunol. 2019 Jun;56(3):308-321. doi: 10.1007/s12016-017-8648-x. PMID: 28963611.

[22] Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients. Molecules. 2020 Dec 4;25(23):5725. doi: 10.3390/molecules25235725. PMID: 33291581; PMCID: PMC7731255

[23] Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020 Mar 24;8(1): e35. PMID: 32232218; PMCID: PMC7096724.

[24] Marhl M, Grubelnik V, Magdič M, Marković R. Diabetes and metabolic syndrome as risk factors for COVID-19. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):671-677. doi: 10.1016/j.dsx.2020.05.013. Epub 2020 May 8. PMID: 32438331; PMCID: PMC7205616.

[25] Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. PMID: 32139904; PMCID: PMC7095524.

[26] Seys LJM, Widagdo W, Verhamme FM, Kleinjan A, Janssens W, Joos GF, et al. DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. Clin Infect Dis. 2018 Jan 6;66(1):45-53. doi: 10.1093/cid/cix741. PMID: 29020176; PMCID: PMC7108100.

[27] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27. PMID: 32077115.

[28] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal

COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020

Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23. PMID:

32335169; PMCID: PMC7177098.

[29] Shi L, Wang Y, Wang Y, Duan G, Yang H. Dyspnea rather than fever is a risk factor for

predicting mortality in patients with COVID-19. J Infect. 2020 Oct;81(4):647-679. doi:

10.1016/j.jinf.2020.05.013. Epub 2020 May 15. PMID: 32417316; PMCID:

PMC7228739.

[30] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. Global

COVID-19 Thrombosis Collaborative Group, endorsed by the ISTH, NATF, ESVM, and

the IUA, supported by the ESC Working Group on Pulmonary Circulation and Right

Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease:

Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-

Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi:

10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. PMID: 32311448; PMCID:

PMC7164881.

[31] Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al.

Hypercoagulability of COVID-19 patients in intensive care unit: A report of

thromboelastography findings and other parameters of hemostasis. J Thromb Haemost.

2020 Jul;18(7):1738-1742. doi: 10.1111/jth.14850. Epub 2020 Jun 24. PMID: 32302438.

[32] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts

disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target

Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4. PMID: 32296069; PMCID:

PMC7100419.

[33] Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-Inflammatory Parameters

in COVID-19 Cases: A Systematic Review and Meta-Analysis. Front Med (Lausanne).

2020 Jun 9; 7:301. doi: 10.3389/fmed.2020.00301. PMID: 32582743; PMCID:

PMC7295898.

[34] Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19

patients in the emergency room. Biomark Med. 2020 Sep;14(13):1207-1215. doi:

10.2217/bmm-2020-0317. Epub 2020 Jul 21. PMID: 32692248; PMCID: PMC7372996.

[35] Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann

Hematol. 2020 Jun;99(6):1205-1208. doi: 10.1007/s00277-020-04019-0. Epub 2020 Apr

15. PMID: 32296910; PMCID: PMC7156897.

[36] Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Laboratory

predictors of death from coronavirus disease 2019 (COVID-19) in the area of

Valcamonica, Italy. Clin Chem Lab Med. 2020 Jun 25;58(7):1100-1105. doi:

10.1515/cclm-2020-0459. PMID: 32573995.

[37] Eastin C, Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China: Guan

W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI:

10.1056/NEJMoa2002032. J Emerg Med. 2020 Apr;58(4):711–2. doi:

10.1016/j.jemermed.2020.04.004. Epub 2020 Jun 3. PMCID: PMC7266766.

[38] Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in

predicting the severity of COVID-19. J Med Virol. 2020 Oct;92(10):2188-2192. doi:

10.1002/jmv.26031. Epub 2020 Jun 2. PMID: 32436996; PMCID: PMC7280691.

[39] Sulejmani A, Galimberti E, Giacobone C, Milano A, Scopetta E, Intra J, et al. Baseline

characteristics of COVID-19 Italian patients admitted to Desio Hospital, Lombardy: a

retrospective study. Scand J Clin Lab Invest. 2021 Feb;81(1):18-23. doi:

10.1080/00365513.2020.1846211. Epub 2021 Jan 6. PMID: 33403882.

[40] Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and

Treatment of Coronavirus (COVID-19). 2021 Apr 20. In: StatPearls [Internet]. Treasure

Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32150360.

[41] Lalueza A, Ayuso B, Arrieta E, Trujillo H, Folgueira D, Cueto C, et al; INFLUDOC

group. Elevation of serum ferritin levels for predicting a poor outcome in hospitalized

patients with influenza infection. Clin Microbiol Infect. 2020 Nov;26(11): 1557.e9-

1557.e15. doi: 10.1016/j.cmi.2020.02.018. Epub 2020 Feb 28. PMID: 32120038.

[42] Schuetz P.The Role of Procalcitonin for Risk Assessment and Treatment of COVID-19

Patients. HealthManagement. 2020;20(5):380-82.

[43] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical

characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a

descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-

6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.

[44] Lu H, Ai J, Shen Y, Li Y, Li, T, Zhouet X ,et al. A descriptive study of the impact of

diseases control and prevention on the epidemics dynamics and clinical features of SARS-

CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention.

medRxiv 2020.02.19.20025031; doi: https://doi.org/10.1101/2020.02.19.20025031.

[Online ahead of print].

[45] Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and

Management. AJR Am J Roentgenol. 2020 Jun;214(6):1280-1286. doi:

10.2214/AJR.20.22954. Epub 2020 Mar 4. PMID: 32130038.

[46] Hafez MAF. The mean severity score and its correlation with common computed

tomography chest manifestations in Egyptian patients with COVID-2019 pneumonia.

Egypt J Radiol Nucl Med. 2020;51(1):254. doi: 10.1186/s43055-020-00368-y. Epub 2020

Dec 8. PMCID: PMC7721816.

[47] Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019 (COVID-19)

Pneumonia in 62 Patients in Wuhan, China. AJR Am J Roentgenol. 2020

Jun;214(6):1287-1294. doi: 10.2214/AJR.20.22975. Epub 2020 Mar 5. PMID: 32134681.

[48] Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT Severity Score: An

Imaging Tool for Assessing Severe COVID-19. Radiol Cardiothorac Imaging. 2020 Mar

30;2(2): e200047. doi: 10.1148/ryct.2020200047. PMID: 33778560; PMCID:

PMC7233443.

Table 1: Sociodemographic characteristics and co-morbidities of all studied patients and

according to COVID-19 severity and mortality.

		TOTAL	SEVERITY			MORTALITY		
			Non-severe	Severe	p-value	Survivors	Non-survivors	p-value
		N=180	N=130	N=50		N= 155	N= 25	
Age (years)	Median (IQR)	48.0 (15-94)	43 (15-94)	60 (22-91)	**0.004**	45.0 (15-94)	57.0 (27-80)	**0.005**
Sex n., %	Male	63 (35.0%)	41 (31.5%)	22 (44.0%)	0.116	53 (34.2%)	10 (40.0%)	0.572
	Female	117 (65.0%)	89 (68.5%)	28 (56.0%)		102 (65.8%)	15 (60.0%)	
Co-morbidities n., %	Diabetes	84 (46.7%)	49 (37.7%)	35 (70.0%)	**≤0.001**	67 (43.2%)	17 (68.0%)	**0.021**
	HTN	65 (36.1%)	36 (27.7%)	29 (58.0%)	**≤0.001**	49 (31.6%)	16 (64.0%)	**0.002**
	IHD	25 (13.9%)	14 (10.8%)	11 (22.0%)	**0.051**	18 (11.6%)	7 (28.0%)	**0.028**
	Stroke	9 (5.0%)	3 (2.3%)	6 (12.0%)	**0.008**	4 (2.6%)	5 (20.0%)	**0.003**
	CKD	8(4.4%)	1 (0.8%)	7 (14.0%)	**≤0.001**	6 (3.9%)	2 (8.0%)	0.353
	CLD	36 (20.0%)	20 (15.4%)	16 (32.0%)	**0.013**	31 (20.0%)	5 (20.0%)	1.000
	COPD	60 (33.3%)	35 (26.9%)	25 (50.0%)	**0.003**	52 (33.5%)	8 (32.0%)	0.879

486   *CKD: chronic kidney disease; CLD, chronic liver disease; COPD: chronic obstructive*

487   *pulmonary disease; HTN, hypertension; IHD: ischemic heart disease. Significance (P-value) was*

488   *set at ≤0.05.*

Table 2: Clinical characteristics and outcomes of all studied patients and according to COVID-19 severity and mortality.

		TOTAL	SEVERITY			MORTALITY		
			Non-severe	Severe	p-value	Survivors	Non-survivors	p-value
		N=180	N=130	N=50		N= 155	N= 25	
Symptoms n., (%)	Fatigue	163 (90.6%)	119 (91.5%)	44 (88.0%)	0.467	142 (91.6%)	21 (84.0%)	0.227
	Fever	125 (69.4%)	89 (68.5%)	36 (72.0%)	0.644	109 (70.3%)	16 (64.0%)	0.524
	Dyspnea	125 (69.4%)	88 (67.7%)	37 (74.0%)	0.411	103 (66.5%)	22 (88.0%)	**0.030**
	Arthralgia	133 (73.9%)	93 (71.5%)	40 (80.0%)	0.247	115 (74.2%)	18 (72.0%)	0.817
	Myalgia	135 (75.0%)	98 (75.4%)	37 (74.0%)	0.848	115 (74.2%)	20 (80.0%)	0.534
	Cough	124 (68.9%)	86 (66.2%)	38 (76.0%)	0.201	104 (67.1%)	20 (80.0%)	0.196
	Anosmia	37 (20.6%)	28 (21.5%)	9 (18.0%)	0.599	34 (21.9%)	3 (12.0%)	0.254
	Rhinitis	18 (10.0%)	16 (12.3%)	2 (4.0%)	0.096	17 (11.0%)	1 (4.0%)	0.281
	Headache	65 (36.1%)	46 (35.4%)	19 (38.0%)	0.744	55 (35.5%)	10 (40.0%)	0.663
	Chest tightness	71 (39.4%)	50 (38.5%)	21 (42.0%)	0.664	57 (36.8%)	14 (56.0%)	0.068
	Sore throat	26 (14.4%)	19 (14.6%)	7 (14.0%)	0.916	23 (14.8%)	3 (12.0%)	0.708
	Nausea	22 (12.2%)	18 (13.8%)	4 (8.0%)	0.283	20 (12.9%)	2 (8.0%)	0.487
	Diarrhea	20 (11.1%)	16 (12.3%)	4 (8.0%)	0.410	19 (12.3%)	1 (4.0%)	0.223
	Loss of taste	12 (6.7%)	11 (8.5%)	1 (20.0%)	0.120	11 (7.1%)	1 (4.0%)	0.565
	Thrombosis	48 (26.7%)	29 (22.3%)	19 (38.0%)	**0.030**	39 (25.2%)	9 (36.0%)	0.255
CT-SS	Median (IQR)	16.5 (0-24)	15 (0-24)	21 (5-23)	**≤0.001**	7 (0-23)	20 (0-24)	**≤0.001**
ICU admission	n., (%)	55 (30.6%)	7 (5.4%)	48 (96.0%)	**≤0.001**	35 (22.6%)	20 (80.0%)	**≤0.001**
Hospital stay (days)	Median (IQR)	14 (3-29)	10 (3-22)	22 (10-29)	**≤0.001**	12 (3-29)	22 (3-29)	**0.001**
In-hospital mortality n., (%)	Discharged alive	155 (86.1%)	121 (93.1%)	34 (68.0%)	**≤0.001**			
	Died	25 (13.9%)	9 (6.9%)	16 (32.0%)	**≤0.001**			

CT-SS: CT-scoring system. Significance (P-value) was set at ≤0.05.

492   **Table 3:** Baseline laboratory findings of all studied patients and according to COVID-19

493   severity and mortality.

	TOTAL	SEVERITY			MORTALITY		
		Non-severe	Severe	p-value	Survivors	Non-survivors	p-value
	n=180	n=130	n=50		n= 155	n= 25	
TLC (×10³/μl)	7.6 (0.1-79.0)	7.5 (1.2-79.0)	7.9 (0.1-24.0)	0.856	7.6 (0.1-79.0)	7.6 (1.2-21.6)	0.849
NL (×10³/μl)	2.5 (0.9-5.8)	1.9 (0.9-4.2)	2.9 (0.9-5.8)	≤0.001	2.1 (0.9-4.2)	2.6 (0.9-5.8)	**0.001**
LYMPH (×10³/μl)	1.2 (0.0-6.0)	1.5 (0.1-6.6)	0.9 (.0-3.6)	≤0.001	1.3 (0.0-6.6)	1.1 (0.1-2.4)	**0.005**
HB (gm/dl)	11.4 (2.9-16.7)	11.5(5.0-16.7)	10.5 (2.9-15.0)	0.280	11.2 (2.9-16.7)	12.4 (6.6-15.2)	0.104
PLT (×10³/μl)	251.5 (6-716)	254.0 (6-716)	240.0 (11-650)	0.627	256.0 (6-716)	208.0 (6-485)	0.124
Ferritin (ng/mL)	371.5 (16-4947)	215.5 (16-2273)	860.5 (130-4947)	≤0.001	342.0(16-4947)	878 (130-2577)	≤0.001
PCT (ng/mL)	0.9 (0-5.9)	0.8 (0.0-5.1)	2.8 (0.4-5.9)	≤0.001	0.9 (.0-5.9)	2.5 (0.6-5.9)	≤0.001
ESR (mm/h)	70.0 (12-210)	57.0 (12-140)	110.0 (49-210)	≤0.001	65.0 (12-187)	110 (30-210)	≤0.001
CRP (mg/L)	48.0 (6.0-378.0)	29.5 (6.0-372.0)	102.5 (11-378.0)	≤0.001	45.0 (6.0-378)	91 (10-304)	**0.007**
D-dimer (mg/L)	1.1 (0.1-12.5)	0.8 (0.1-12.5)	2.5 (0.7-12.2)	≤0.001	0.9 (0.1-9.5)	3.4 (0.6-12.5)	≤0.001
LDH (IU/L)	222.0 (18-1889)	189.0 (18-1889)	392.0 (46-1121)	≤0.001	207 (18-1889)	388 (123 -1091)	**0.002**
AST (IU/L)	26.0 (2-2044)	25.0 (11-2044)	45.0 (2-898)	**0.018**	25 (2-2044)	45 (12-898)	**0.002**
ALT (IU/L)	30.0 (10-1344)	25.0 (10-1344)	45.0 (10-511)	≤0.001	27 (10-1344)	45 (18-511)	**0.001**

ALT: Alanine amino transferase; AST: Aspartate aminotransferase; CRP: C-reactive protein;

ESR: Erythrocyte sedimentation rate; HB: Hemoglobin; LDH: Lactate dehydrogenase; Lymph:

Lymphocytes; PCT: Procalcitonin; PLT: Platelets; NL: Neutrophils; TLC: Total leukocytic

count. Data presented as median (IQR). Significance (P-value) was set at ≤0.05.

Table 4: Multivariate logistic regression analysis of risk factors associated with COVID-19

severity and in-hospital mortality.

Variables	SEVERITY				
	B	S.E.	P-value	Odds ratio	95% CI
Diabetes	1.082	0.518	**0.037**	2.951	1.070-8.137
COPD	1.192	0.516	**0.021**	3.294	1.199-9.053
CT-SS ($\geq$ 17)	1.416	0.673	**$\leq$ 0.001**	1.205	1.089-1.334
Ferritin ($\geq$ 350 ng/mL)	2.405	0.702	**0.001**	11.08	2.796-41.551
AST ($\geq$ 40 IU/L)	1.124	0.487	**0.021**	3.07	1.842-7.991
Lymphocytes ($< 1\times10^{3}$/μL)	1.387	0.448	**0.005**	4.002	1.537-10.421
	MORTALITY				
Dyspnea	1.388	0.686	**0.043**	4.006	1.045-15.359
CT-SS ($\geq$ 17)	2.023	0.792	**0.002**	1.271	1.091-1.482
AST ($\geq$ 40 IU/L)	1.061	0.497	**0.033**	2.89	1.091-7.661

500   *AST: Aspartate aminotransferase; COPD: Chronic obstructive pulmonary disease; CT-SS: CT-*

501   *scoring system. Significance (P-value) was set at ≤0.05.*